Journal
MAGNETIC RESONANCE IN MEDICINE
Volume 58, Issue 1, Pages 119-127Publisher
JOHN WILEY & SONS INC
DOI: 10.1002/mrm.21271
Keywords
prostate neoplasm; blood flow; perfusion; HIFU therapy; contrast agent
Ask authors/readers for more resources
Our aim was to evaluate the influence of regional prostate blood flow (rPBF) on high-intensity focused ultrasound (HIFU) treatment outcome. A total of 48 patients with clinically localized prostate cancer were examined by dynamic contrast-enhanced (DCE)-MRI prior to HIFU therapy. A prostate-specific antigen (PSA) nadir threshold of 0.2 ng/ml was used to define the populations of responders and nonresponders. A dedicated tracer kinetic model, namely monoexponential plus constant (MPC) deconvolution, was implemented to provide quantitative estimates of rPBF. The results were compared with those obtained by semiquantitative (steepest slope, mean gradient) and quantitative (Fermi deconvolution) approaches. Of the four methods studied, quantitative rPBF obtained by MPC deconvolution proved the most sensitive to the perfusion changes encountered in this study. Furthermore, blood-flow values obtained with MPC deconvolution in the prostate and muscle (12 +/- 8 and 5 +/- 3 ml/min/100 g, respectively) were in good agreement with literature data. The mean pretreatment rPBF obtained with MPC deconvolution was significantly higher in nonresponders compared to responders (16 +/- 9 vs. 10 +/- 6 ml/min/100 g), suggesting a correlation between baseline perfusion and treatment outcome. The present work describes and validates the use of dynamic MRI to estimate rPBF in patients, which in the future may help to refine the conduct of HIFU therapy. Magn Reson Med 58:119-127, 2007. (c) 2007 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available